Gemphire Therapeutics to Report Third Quarter Financial Results and Corporate Update on November 2; Corporate Presentation at the 25th Annual Credit Suisse Healthcare Conference on November 7
The Company also announced that
25th Annual Credit Suisse Healthcare Conference Presentation Details: | |
Date: | Monday, November 7 |
Time: | 10:00am Mountain Time/12:00pm Eastern Time |
Location: | Phoenician Hotel, Ballroom G |
The presentation slides will be available immediately prior to and for 90 days following the presentation on the Investors and Media page of Gemphire’s website at http://ir.gemphire.com.
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH (nonalcoholic fatty liver disease). Please visit www.gemphire.com for more information.
Contact:Andrew McDonald , Ph.D.LifeSci Advisors, LLC (646) 597-6987Jeff Mathiesen , CFOGemphire Therapeutics (734)-245-1700